A Phase 3 Double-blind Placebo-controlled Randomized Study to Assess the Efficacy and Safety of Epicutaneous Immunotherapy with DBV712 250 g in 4-7-year-old Children with Peanut Allergy

Go Back to All Clinical Trials

A Phase 3 Double-blind Placebo-controlled Randomized Study to Assess the Efficacy and Safety of Epicutaneous Immunotherapy with DBV712 250 g in 4-7-year-old Children with Peanut Allergy

Brief description of study

This is a 12-month, Phase 3, double-blind, placebo-controlled, randomized study to assess the efficacy and safety of daily DBV712 250 µg in peanut-allergic children aged 4-7 years. The overall maximum study duration for each subject is approximately 58 weeks: 4-week Screening Period, 12-month Treatment Period and 2-week Follow-up Period.

Clinical Study Identifier: s23-00262

ClinicalTrials.gov Identifier: NCT05741476

Principal Investigator: Anna H Nowak-Wegrzyn.

Other Investigator: Kanwaljit Brar.

Contact the research team to learn more about this study.

Your Email

Not a valid e-mail address

Please Provide Email Address

First Name

First name is mandatory

Last Name

Your Phone

Please provide phone number

Invalid phone number

Valid phone number

Comments

Send Confirmation of This To Me

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

Clinical Research Studies